COVID-19 outbreak

Latest updates on the coronavirus and heart disease

Find out more

Our Global Partners

Using Heart together,
because every heartbeat matters

Home > World Heart Day 2020 > Our Global Partners

World Heart Day is proud to partner with AstraZeneca, Boehringer Ingelheim and Lilly alliance, and Pfizer

Our global partners help us tirelessly in our movement to reduce cardiovascular disease (CVD) around the world.

This World Heart Day, we’ve joined forces to make World Heart Day more powerful than ever. With their support, we are raising awareness and encouraging individuals, families, communities and governments to drive the CVD agenda and help people live longer, better, more heart-healthy lives.

Thank you to AstraZeneca, Boehringer Ingelheim and Lilly alliance, and Pfizer, our official global partners for World Heart Day, for their collaboration.

AstraZeneca

AstraZeneca’s aim is to protect the lives of millions of people in the next year from the often-devastating consequences of heart failure, cardiovascular, metabolic and renal diseases.

To drive global action to prevent, control, and reduce the burden of cardiovascular disease and its associated risks and complications, AstraZeneca and the World Heart Federation will work in close collaboration. We will tackle key issues in cardiovascular care and associated complications through global policy, advocacy and disease awareness initiatives, and by supporting global and local activations to assist those at particularly high risk.

Our partnership will help raise much-needed awareness to support those people living with heart failure, cardiovascular, metabolic and renal diseases manage their condition and live longer, healthier lives.

Boehringer Ingelheim and Lilly alliance

The Boehringer Ingelheim and Lilly alliance is committed to improving both the quality of life and health outcomes of people living with diabetes. A key part of our work is to alert people to the serious link between type 2 diabetes, heart disease and other health conditions. In people with diabetes, heart and kidney disorders often coexist – the cardio-renal-metabolic systems are intimately linked. People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes, and over a third of people with diabetes or heart failure also have chronic kidney disease.

This World Heart Day, we are proud to continue to support the World Heart Federation. Today, there are around 425 million adults in the world living with diabetes, and half of these people are expected to die early due to heart disease. Even when blood sugar levels are under control, having type 2 diabetes means that there is an increased risk of a heart attack or stroke.

The good news, however, is that diabetes and cardiovascular guidelines encourage healthcare professionals across the world to pay more attention than ever before to the heart when treating people with type 2 diabetes. Our focus is to help spark conversations between people with type 2 diabetes and their healthcare professional about the risk of heart disease.

We all need to work together, so people with type 2 diabetes have the best chance possible of protecting their heart.

Pfizer

This World Heart Day, we are proud to partner with the World Heart Federation to support their mission to achieve heart health equity for all.

At Pfizer, we are united by a single purpose – to deliver breakthroughs that change patients’ lives. Every day, Pfizer colleagues from around the world work to address areas of significant unmet medical need. Nowhere is this need greater than in rare disease.

There are more than 7,000 known rare diseases. One of these is called transthyretin amyloid cardiomyopathy or ATTR-CM, which is a form of cardiac amyloidosis. ATTR-CM is a rare, underdiagnosed, and fatal condition, resulting in progressive heart failure.

This year, we continue our partnership with the World Heart Federation to support the cardiology community and share how we at Pfizer, ‘use heart.’ We ‘use heart’ to pioneer innovation. We ‘use heart’ to champion health equity. We ‘use heart’ to improve care for all those living with cardiovascular disease, including those living with rare conditions, such as ATTR-CM. This year, we hope to inspire others to share how they ‘use heart’ to support the cardiac amyloidosis community.

Thanks also to our official World Heart Day supporters who are helping to amplify our voice around the world

If you are interested in joining us as an official partner of World Heart Day and helping even more people to make better heart choices, talk to us today at partnerships@worldheart.org

Become a WHD sponsor or partner

Contact us